Radiation therapy after radical surgery in prostate cancer

Pembrolizumab benefits patients with brain metastases

FOLFOX with selective use of 5FUCRT is non-inferior to 5FUCRT for treatment of LARC prior to low anterior resection with TME

Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma

ADCLEC.syn1 and CD33-CARS in humanised acute myeloid leukaemia models shows promising efficacy

Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard regimens

A randomised trial of the FLT3 inhibitor gilteritinib as post-transplant maintenance for FLT3-ITD AML

Single infusion of cilta-cel sees longer median PFS than any previously reported therapy in heavily pretreated RRMM

Atezolizumab, obinutuzumab and venetoclax combination is active and leads to durable remissions in previously untreated DLBCL-RS

Addition of blinatumomab to mini-hyper-CVD and inotuzumab improves outcomes in R/R ALL

Chemotherapy-free combination of ponatinib and blinatumomab results in high rates of CMR and NGS MRD negativity in Ph positive ALL

Ponatinib superior to imatinib in combination with reduced-intensity chemotherapy in newly diagnosed Ph positive ALL